首页> 外文OA文献 >Outcomes of Donor Lymphocyte Infusion for Treatment of Mixed Donor Chimerism after a Reduced-Intensity Preparative Regimen for Pediatric Patients with Nonmalignant Diseases

【2h】

Outcomes of Donor Lymphocyte Infusion for Treatment of Mixed Donor Chimerism after a Reduced-Intensity Preparative Regimen for Pediatric Patients with Nonmalignant Diseases

机译：小剂量非恶性疾病患者低剂量的制备治疗后输注供体淋巴细胞治疗混合供体嵌合体的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Haines Hilary L.; Bleesing Jack J.; Davies Stella M.; Hornung Lindsey; Jordan Michael B.; Marsh Rebecca A.; Filipovich Alexandra H.;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Outcomes of Donor Lymphocyte Infusion for Treatment of Mixed Donor Chimerism after a Reduced-Intensity Preparative Regimen for Pediatric Patients with Nonmalignant Diseases [J] . Haines Hilary L., Bleesing Jack J., Davies Stella M., Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2015,第2期

机译：小剂量非恶性疾病患者低剂量的制备治疗后输注供体淋巴细胞治疗混合供体嵌合体的结果
2. Comparison of second transplantation and donor lymphocyte infusion for donor mixed chimerism after allogeneic stem cell transplantation for nonmalignant diseases [J] . Umeda Katsutsugu, Adachi Souichi, Tanaka Shiro, Pediatric blood & cancer . 2016,第12期

机译：非恶性疾病同种异体干细胞移植后第二次移植和供体淋巴细胞输注对供体混合嵌合的比较
3. Mixed T-cell chimerism at 3 months followed by donor lymphocyte infusion is independently associated with favorable outcomes in alemtuzumab-based reduced-intensity allogeneic hematopoietic stem cell transplantation [J] . Leukemia and lymphoma . 2020,第1a2期

机译：3个月的混合T细胞嵌合术后，供体淋巴细胞输注与Alemtuzumab的减少强度同种异体造血干细胞移植的有利结果独立相关
4. Anti-Thymocyte-Globulin (ATG-Fresenius) for Prevention of Acute and Chronic Graft-versus-Host Disease in Pediatric and Adult Recipients of Unrelated Donor Bone Marrow Transplantation [C] . . 2006

机译：抗胸腺细胞球蛋白（ATG-Fresenius）预防无关供体骨髓移植的小儿和成年患者的急性和慢性移植物抗宿主病
5. Donor specific tolerance to rat hindlimb allografts with mixed cell chimerism [D] . Hiotis, Spiros P. 1998

机译：供体对大鼠后肢同种异体移植混合细胞的特异性耐受
6. Experience with Alemtuzumab Fludarabine and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease Stem Cell Source and Alemtuzumab Regimen [O] . Rebecca A. Marsh, Marepalli B. Rao, Aharon Gefen, -1

机译：在非恶性疾病患者中使用Alemtuzumab氟达拉滨和美法仑降低强度的条件进行造血细胞移植的经验显示出良好的结果并且混合嵌合体的风险取决于基础疾病干细胞来源和Alemtuzumab方案
7. Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen [O] . Marsh Rebecca A., Rao Marepalli B., Gefen Aharon, 2015

机译：在非恶性疾病患者中使用Alemtuzumab，氟达拉滨和美法仑降低强度的条件进行造血细胞移植的经验显示出良好的结果，并且混合嵌合体的风险取决于基础疾病，干细胞来源和Alemtuzumab方案

Outcomes of Donor Lymphocyte Infusion for Treatment of Mixed Donor Chimerism after a Reduced-Intensity Preparative Regimen for Pediatric Patients with Nonmalignant Diseases

著录项

引文网络

相似文献

相关主题

期刊订阅